Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration

Executive Summary

Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.

Advertisement

Related Content

J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
J.P. Morgan Executive Roundtable, Part 2: Women In Biopharma And The Path Forward
J.P. Morgan Executive Roundtable, Part 1: How To Help Women Move Into The Biopharma C-Suite
Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair
Maruho Broadens Derma Horizons Through Dual Licensing Deals
Hanmi Does It Again - RAF Inhibitor Goes To Genentech In $910m Deal
Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy
Boehringer Increasingly Looking Outside For Oncology Growth
Zymeworks, GSK Sign Antibody Deal For Up To $440m

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register